Coagulopathy in Cirrhosis

Shakira Laing

Background

  • The liver produces most pro-coagulant factors (II, V, VII, IX, X, XI) and anticoagulants (protein C, S, antithrombin). Factor VIII and von Willebrand factor are produced by endothelial cells, not hepatocytes. 
  • Thrombocytopenia results from splenic sequestration (portal hypertension), decreased thrombopoietin production, and bone marrow suppression. 
  • Cirrhosis causes complex hemostatic changes affecting both pro- and anticoagulant pathways. Current understanding recognizes a rebalanced hemostatic state rather than an overall bleeding tendency.

Evaluation

  • INR/PT and PTT poorly predict bleeding risk in cirrhosis and should not guide transfusion decisions. 
  • Viscoelastic testing (TEG/ROTEM) provides a more comprehensive assessment but lacks validated transfusion thresholds.

Preprocedural Prophylaxis

  • Low-risk procedures (paracentesis, thoracentesis, variceal banding): No routine blood products or specific INR/platelet cutoffs required
  • Routine preprocedural testing not recommended in stable cirrhosis with known baseline abnormalities

Active Bleeding

  • Vitamin K: Not routinely recommended; does not improve outcomes in cirrhotic coagulopathy per 2025 ACG guidelines. (can be considered if thought to be from nutritional deficiency) 
  • FFP: Avoid routine use; only consider as part of balanced massive transfusion or if TEG suggests benefit (increases portal pressure, contains anticoagulants) 
  • Cryoprecipitate: If fibrinogen 120 mg/dL 
  • Platelets: No specific target for bleeding; consider >50,000 for high-risk procedures or active bleeding 
  • Preferred agents: Low-volume cryoprecipitate or 4-factor prothrombin complex concentrate over FFP

TEG-Guided Transfusion

  • Reduces blood product use without increasing bleeding risk
  • Specific cutoffs not standardized; institutional protocols vary 
  • One validated approach: FFP if R-time >40 min; platelets if MA 30 mm

VTE Prophylaxis

  • Recommended for hospitalized cirrhotic patients meeting standard VTE prophylaxis criteria 
  • Thrombocytopenia and elevated INR are not absolute contraindications 
  • Relative contraindications: Active hemorrhage, recent variceal bleeding (before healing), severe thrombocytopenia (<50,000) - use clinical judgment 
  • Preferred agent: LMWH or fondaparinux over UFH (Unless patient has fluctuating creatinine/AKI)
Last updated on